Axsome Therapeutics, Inc. (AXSM): Total Assets
$689.80M
As of 2025-12-31
$761.45M
As of 2026-06-30
+27.7%
3-year compound annual growth
+30.0%
5-year compound annual growth
+30.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $689.80M | +21.3% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $568.50M | -3.4% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $588.24M | +77.5% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $331.48M | +277.6% | 2024-02-23, Balance as of period end |
| 2021-12-31 | $87.79M | -52.8% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $186.13M | -15.6% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $220.55M | n/m | 2021-03-01, Balance as of period end |
| 2018-12-31 | $15.38M | -56.7% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $35.56M | -7.0% | 2019-03-15, Balance as of period end |
| 2016-12-31 | $38.21M | -22.1% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $49.08M | n/a | 2017-03-07, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $689.80M | +21.3% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $1.06B | +84.1% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $1.93B | -12.2% |
| Insmed Inc (INSM) | 2025-12-31 | $2.26B | +11.8% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.53B | +1.9% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $763.63M | +31.5% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.45B | +6.2% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $1.63B | +3.3% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $598.73M | +20.3% |
Compare AXSM, TGTX, OPK, INSM side by side · Screen every company in Pharmaceutical Preparations ↗